SPOTLIGHT: Glumetza approved in Canada

Canada's Biovail and Depomed have received Canadian regulatory approval for Glumetza for Type 2 diabetes. The companies are also expecting a decision from the FDA on Glumetza, which earned an "approvable" letter from the agency. Release

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.